Applying Shared Decision-Making to ER+/HER2- Metastatic Breast Cancer Care

Selecting Therapy for ER+/HER2- Metastatic Breast Cancer: Key Factors to Consider

ReachMD Healthcare Image
RestartResume

What factors should drive our treatment decisions for patients with ER+/HER2- metastatic breast cancer?

  • Overview

    From disease-related factors to the latest clinical trial data, there’s a lot to consider when selecting a therapy for patients with ER+/HER2- metastatic breast cancer. Here with Dr. Charles Turck to break down the key factors that can guide our treatment selections is breast medical oncologist Dr. Megan Kruse from the Cleveland Clinic in Ohio.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free